ImmuKnow: Immune Cell Function Assay

ImmuKnow: Immune Cell Function Assay

  • Print

Immunosuppression Modifications Based on an Immune Response Assay: Results of a Randomized, Controlled Trial1

Outcomes-based data show:

  • Increased Patient Survival: 1 year post-transplant
  • Reduced Infections: > 2 weeks post-transplant
  • Lowered Immunosuppressant Dosage
  • Immune Cell Function Tacrolimus Dosage Instructions

     

     

     

     

     

     

    Immune Cell Function Data Results

     

     

     

     

    Kowalki Curve Risk Analysis

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


    Viracor-IBT can help you get results faster when it matters most, with the following tests to aid in the diagnosis and differentiation of solid organ transplant (SOT) complications.

    Testing for Key SOT Complications

    For more information on Immune Cell Function testing, new study data or how ImmuKnow can help your patients,
    please call client services at 800.305.5198

    EMAIL US

    1Ravaioli M, Neri F, et al. Immunosuppression Modifications Based on an Immune Response Assay: Results of a Randomized, Controlled Trial. Transplantation. Epub 2015 March 9.

    2Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation. 2006;82:663-668.

    ImmuKnow® is FDA cleared for the following Intended Use: Detection of cell-mediated immune response in populations undergoing immunosuppressive therapy for organ transplant. Product Insert 2015. Viracor-IBT Laboratories, Lee’s Summit, MO.